deferoxamine

deferoxamine
Name	Deferoxamine
Tradename	Desferal, others
Routes of administration	Intravenous, intramuscular, subcutaneous, topical
Legal status	Prescription only
Bioavailability	Variable (parenteral)
Metabolism	Minimal hepatic metabolism
Elimination half-life	~20–30 minutes (plasma); longer for iron-bound complexes
Excretion	Renal
Cas number	70-51-9
Atc prefix	V03
Atc suffix	AC02
Pubchem	439501
Drugbank	DB00652
Chemspiderid	388970
Chebi	28697
Kegg	D00328
Synonyms	Desferrioxamine B, DFO
Molecular formula	C25H48N6O8
Molar mass	560.67 g/mol

deferoxamine

Deferoxamine is a bacterial-derived iron chelator used clinically to treat acute and chronic iron overload and to bind other trivalent metals. It is administered parenterally for systemic effect and occasionally topically for localized metal binding. The agent has shaped management of transfusion-related hemosiderosis and has featured in toxicology, hematology, and transplant medicine.

Medical uses

Deferoxamine is indicated for treatment of transfusion-induced iron overload in conditions such as Thalassemia, Sickle cell disease, and chronic anemias requiring repeated transfusions in settings including Bone marrow transplant care and hereditary sideroblastic anemias. It is used in acute iron poisoning management alongside supportive measures and is sometimes employed for aluminum toxicity in patients receiving dialysis associated with Aluminum exposure from contaminated dialysate or aluminum-containing phosphate binders. Off-label institutional uses have included adjunctive therapy in post-transplant iron management and perioperative optimization in centers affiliated with institutions such as Mayo Clinic, Johns Hopkins Hospital, and Massachusetts General Hospital.

Mechanism of action

Deferoxamine is a hexadentate siderophore originally produced by Streptomyces species that chelates ferric iron (Fe3+) with high affinity, forming ferrioxamine complexes that are excreted primarily via the kidneys. Binding of Fe3+ prevents participation in Fenton chemistry responsible for hydroxyl radical generation implicated in oxidative injury described in works by researchers at NIH and Oxford University. The chelation mechanism also explains clinical reversal of iron-mediated organ damage documented in case series from centers such as UCLA and Cleveland Clinic.

Pharmacology

Pharmacokinetic profiles have been characterized in studies from institutions including Stanford University and University of Pennsylvania, showing rapid plasma clearance with short half-life for unbound deferoxamine and prolonged persistence when iron-bound. Parenteral administration routes—intravenous infusion, intramuscular injection, and continuous subcutaneous infusion—are chosen based on regimens developed in multicenter trials involving groups like European Medicines Agency-sponsored networks and the US FDA-regulated protocols. Renal excretion of ferrioxamine predominates; hepatic metabolism is minimal, a finding reproduced in pharmacology reports from Harvard Medical School. Deferoxamine displays limited oral bioavailability, prompting development of oral chelators such as deferasirox in comparative studies involving AstraZeneca and other pharmaceutical companies.

Adverse effects and toxicity

Common adverse events include local reactions at infusion sites and systemic reactions such as hypotension and rash, as documented in safety reports submitted to regulatory bodies like the US FDA and European Medicines Agency. Prolonged therapy is associated with ototoxicity and visual impairment, necessitating surveillance strategies recommended in guidelines from organizations including World Health Organization-affiliated panels and the American Society of Hematology. Infusion-related infections have been observed in reports from transplant centers such as Fred Hutchinson Cancer Center, and rare immune-mediated reactions mirror case reports in journals edited by publishers like Springer and Elsevier. Over-chelation can precipitate iron deficiency and trace metal disturbances, highlighted in position statements by groups such as the British Society for Haematology.

History and development

Deferoxamine was isolated from Streptomyces pilosus and developed in mid-20th-century antibiotic and siderophore research conducted at institutions including Rockefeller University and University of Cambridge. Clinical translation into iron chelation therapy followed trials coordinated by hospitals such as Children's Hospital Boston and Great Ormond Street Hospital, with regulatory approvals processed through agencies like the US FDA. The compound’s role in modern hematology expanded after longitudinal cohort studies led by investigators at Monash University and Karolinska Institutet, and it influenced the development of oral chelators by pharmaceutical firms including Novartis and Janssen.

Research and other applications

Research has explored deferoxamine’s neuroprotective potential in models of ischemia studied at laboratories affiliated with Columbia University, University of California, San Diego, and Imperial College London, due to its capacity to limit iron-mediated oxidative injury. It has been evaluated in wound healing and dermatologic contexts in trials run by centers like University of Miami and Mount Sinai Health System, where topical formulations were tested. Other investigational uses include modulation of iron in infectious disease research at CDC-linked projects and investigations into chelation effects in neurodegenerative disorders pursued at National Institute on Aging and Scripps Research. Preclinical and translational studies continue in academic consortia involving institutions such as ETH Zurich, University of Tokyo, and Peking University.

Category:Iron chelators Category:Antidotes Category:Drugs acting on the blood